Banner

Measures Beyond A1C: Achieving and Maintaining Glycemic Management in People with Type 2 Diabetes

Release Date: August 26, 2021
Expiration Date: February 28, 2022

Launch Presentation Download Handout

While glycated hemoglobin, or A1C, has been used as the gold standard to measure treatment goals and estimate the risk of developing diabetes-related complications in people with type 2 diabetes, A1C is an indirect measure and provides no information about daily glucose fluctuations, hypoglycemia, or hyperglycemia. In this activity, the value of glucose variability metrics and the potential role of glycemic fluctuations within the context of cardiovascular risk management in type 2 diabetes are explored.

Learning Objectives

  • Use glucose profiles to describe the physiology of glucose fluctuations in normal glucose homeostasis and in type 2 diabetes (T2D).
  • Identify the potential clinical relevance of time spent outside the euglycemic range for people with T2D.
  • Discuss the role of glucose variability metrics in guiding treatment in people with T2D.
  • Compare the effects of new glucose-lowering drugs on glucose variability in the setting of T2D.

This webinar is not accredited for continuing education.
 

Faculty

Susan Cornell, Pharm.D., CDCES, FADCES, FAPhA
Associate Director of Experiential Education
Professor of Pharmacy Practice
Midwestern University College of Pharmacy
Downers Grove, Illinois

Disclosures

In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships.

In this activity, only the individual below has disclosed a relevant financial relationship.  All other persons in control of content do not have any relevant financial relationships with an ineligible company.

  • Susan Cornell - Novo Nordisk Inc: advisory board, speaker's bureau

 

As defined by the Standards of Integrity and Independence definition of ineligible company. All relevant financial relationships have been mitigated prior to the activity.

Target Audience

This activity was planned to meet the educational needs of pharmacists and pharmacist decision makers who care for or have an interest in the care of patients with type 2 diabetes.